CJC-1295 / Ipamorelin Blend
Also known as CJC/Ipa Blend, GH Blend
This blend pairs CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH), with ipamorelin, a selective ghrelin-receptor agonist. It is the most widely referenced growth-hormone secretagogue combination, based on the idea that stimulating two distinct receptor pathways produces a larger GH pulse than either peptide alone. Both components have individually been studied for their effects on GH release in humans, though the fixed combination itself has not been evaluated as a distinct product in controlled trials. It is commonly discussed in the context of recovery, body composition, and general anti-aging research. It is not approved for human medical use outside controlled research settings.
Reported benefits
- Amplifies growth-hormone pulse compared with either component alone
- Associated with improved recovery
- Supports lean body composition in research contexts
- Reported to improve sleep quality
- Widely used as a general anti-aging research pairing
How it works
CJC-1295 binds GHRH receptors on pituitary somatotrophs, increasing synthesis and pulsatile release of growth hormone. Ipamorelin independently activates the ghrelin receptor (GHS-R1a), amplifying pulsatile GH release with a comparatively selective profile that is reported to produce less concurrent cortisol and prolactin stimulation than older secretagogues. Because the two act on separate receptor pathways, the combination is described in the literature as producing a synergistic GH pulse larger than either peptide individually.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 200 mcg | once daily at bedtime |
| Moderate | 300 mcg | once daily at bedtime |
| High | 500 mcg | twice daily |
Estimate your dose
Dose estimator
Educational estimate for CJC-1295 / Ipamorelin Blend, scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for CJC-1295 / Ipamorelin Blend. Educational only.
Draw to this mark
6units
= 0.06 mL for a 300 mcg dose
Concentration
5,000 mcg/mL
Doses per vial
33
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
Considered the reference-standard GH secretagogue pairing; often used as the GH-axis backbone alongside recovery-focused peptides such as BPC-157.
Common protocols
Common questions
What is CJC-1295 / Ipamorelin Blend used for?
This blend pairs CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH), with ipamorelin, a selective ghrelin-receptor agonist. It is the most widely referenced growth-hormone secretagogue combination, based on the idea that stimulating two distinct receptor pathways produces a larger GH pulse than either peptide alone. Both components have individually been studied for their effects on GH release in humans, though the fixed combination itself has not been evaluated as a distinct product in controlled trials. It is commonly discussed in the context of recovery, body composition, and general anti-aging research. It is not approved for human medical use outside controlled research settings. Reported benefits include amplifies growth-hormone pulse compared with either component alone, associated with improved recovery, supports lean body composition in research contexts.
What is a typical CJC-1295 / Ipamorelin Blend dose?
Reported ranges run 200-500 mcg. A low protocol is 200 mcg once daily at bedtime, and a high protocol is 500 mcg twice daily. This is reference information, not a dosing recommendation.
What is the half life of CJC-1295 / Ipamorelin Blend?
CJC-1295 without DAC is reported at roughly 30 minutes, while the DAC-modified form extends to several days; ipamorelin is reported at approximately 2 hours. Overall blend duration depends heavily on which CJC-1295 form is used.. That is what sets the dosing frequency, and it is why the timing guidance is ~30 min before bed, empty stomach.
How is CJC-1295 / Ipamorelin Blend administered?
Subcutaneous: into fat, under the skin. Injected subcutaneously into the abdomen, commonly at bedtime or in a fasted state to align with natural growth-hormone pulsatility; both peptides are typically drawn into the same syringe.
How long is a CJC-1295 / Ipamorelin Blend cycle?
8-12 weeks on, followed by 4 weeks off. Cycling is commonly cited to reduce theoretical downregulation of pituitary responsiveness, particularly with DAC-containing formulations.
What are the side effects of CJC-1295 / Ipamorelin Blend?
Reported side effects include water retention, injection site reaction, tingling or flushing, mild increase in hunger, headache. Evidence level for this compound is well studied.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. CJC-1295 / Ipamorelin Blend may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →